PHARMACEUTICAL ASSISTANCE IN THE BRAZILIAN PUBLIC HEALTH SYSTEM (SUS): PHARMACEUTICAL MONITORING IN TREATMENT ADHERENCE AND CONTROL OF CHRONIC DISEASES SUCH AS HYPERTENSION
DOI:
https://doi.org/10.61164/h35y9k67Keywords:
pharmaceutical care, hypertension, therapeutic adherence, primary health care, public healthAbstract
Arterial hypertension remains one of the most prevalent chronic conditions in Brazil, strongly associated with severe cardiovascular outcomes. Within this context, pharmacists play a strategic role in Primary Health Care by supporting therapeutic adherence and improving clinical management. This study aimed to evaluate the impact of pharmaceutical follow-up on treatment adherence and hypertension control within the Brazilian Unified Health System (SUS). The methodology included a literature review in SciELO, LILACS, and PubMed, as well as the analysis of secondary data from DATASUS (2018–2023). Eligible studies addressed pharmaceutical care, therapeutic follow-up, rational medication use, and hypertension management. Results showed a progressive increase in the number of hypertensive patients monitored by pharmacists, accompanied by a reduction in complications related to the disease. Evidence indicates that structured pharmaceutical interventions allow the identification of drug-related problems, optimization of therapeutic regimens, health education, and reinforcement of self-care. Studies also demonstrated improvements in blood pressure control, decreased treatment discontinuation, and greater patient understanding of their therapy. However, challenges such as unequal distribution of professionals, structural limitations, and insufficient implementation of clinical services persist in many regions. The discussion revealed alignment between DATASUS data and literature findings, confirming the positive impact of pharmaceutical monitoring on clinical outcomes. Experiences with digital health tools showed potential as complementary strategies, although their effectiveness depends on sociocultural adaptation and users' health literacy. In conclusion, pharmaceutical follow-up is essential for improving hypertension management and should be strengthened through public policies that expand clinical services, support continuous education, and promote multidisciplinary integration.
Downloads
References
ALBUQUERQUE, K. R. de; BORGES, J. W. P.; RODRIGUES, M. T. P. Não adesão ao tratamento medicamentoso da hipertensão arterial sistêmica na atenção básica de saúde. Cadernos de Saúde Coletiva, Rio de Janeiro, v. 32, n. 1, p. e32010393, 2024. Disponível em: Scielo/BVS. DOI: https://doi.org/10.1590/1414-462x202432010393
ATHAYDE, S. A.; RANGEL, E. M.; GOMES, I. C. (2020). Acompanhamento farmacoterapêutico e adesão ao tratamento em hipertensos na atenção primária: revisão integrativa. Revista Brasileira de Ciências Farmacêuticas, v. 56, n. 3, p. 298-305.
BARROS, D. S. L.; SILVA, D. L. M.; LEITE, S. N. Serviços farmacêuticos clínicos na Atenção Primária à Saúde no Brasil. Trabalho, Educação e Saúde, Rio de Janeiro, v. 18, n. 1, p. e0024071, 2020. DOI: https://doi.org/10.1590/1981-7746-sol00240
BARROSO, W. K. S. et al. Diretrizes Brasileiras de Hipertensão Arterial – 2020. Arquivos Brasileiros de Cardiologia, v. 116, n. 3, 2021.
BRASIL. Ministério da Saúde. (2023). Vigitel Brasil 2023: vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico. Brasília: Ministério da Saúde.
BRASIL. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Assistência Farmacêutica. (2014). Cuidado farmacêutico no SUS: conceitos e práticas. Brasília: Ministério da Saúde. Disponível em: https://bvsms.saude.gov.br
COELHO, J. C. et al. Adesão ao tratamento medicamentoso anti-hipertensivo no Brasil: revisão sistemática e meta-análise. Ciência & Saúde Coletiva, v. 29, n. 8, 2024. DOI: 10.1590/1413-81232024298.19282022EN. DOI: https://doi.org/10.1590/1413-81232024298.19282022en
COELHO, J. C.; GUIMARÃES, M. C. L. P.; PIERIN, Â. M. G. Adesão ao tratamento medicamentoso anti-hipertensivo no Brasil: revisão sistemática e meta-análise. Ciência & Saúde Coletiva, Rio de Janeiro, v. 29, n. 8, p. 1-17, 2024. doi: 10.1590/1413-81232024298.19282022. DOI: https://doi.org/10.1590/1413-81232024298.19282022
COSTA, K. S. et al. Pesquisa Nacional de Saúde 2019: obtenção de medicamentos por adultos em tratamento para hipertensão e diabetes no Programa Farmácia Popular do Brasil. Epidemiologia e Serviços de Saúde, v. 31, supl. 1, e2021366, 2022. DOI: https://doi.org/10.1590/ss2237-9622202200004.especial
DATASUS. Departamento de Informática do SUS. (2024). Banco de dados do Sistema Único de Saúde (TABNET). Disponível em: http://datasus.saude.gov.br.
DE MARCHI, A. C. B. et al. Digital technologies for comprehensiveness in the treatment of hypertension in the Brazilian Unified Health System: non-randomized clinical trial. Interfaces – Revista de Saúde, Humanas e Tecnologia, v. 12, e1, 2024. Disponível em: https://www.gov.br/saude DOI: https://doi.org/10.16891/2317-434X.v12.e1.a2024.pp4031-4041
GOMES, I. S. et al. Pharmaceutical Care in Primary Care: an Experience with Hypertensive Patients in the North of Brazil. International Journal of Cardiovascular Sciences, v. 35, n. 3, 2022. DOI: 10.36660/ijcs.20200257. DOI: https://doi.org/10.36660/ijcs.20200257
OLIVEIRA, D. R. et al. (2019). Adesão ao tratamento medicamentoso em pacientes hipertensos na atenção primária: fatores associados. Cadernos de Saúde Pública, v. 35, n. 5.
OPAS/OMS. Organização Pan-Americana da Saúde. (2022). Doenças Crônicas Não Transmissíveis no Brasil: situação atual e desafios para o enfrentamento. Brasília: OPAS. Disponível em: https://www.paho.org/pt
PEREIRA, N. C. et al. Implementation of pharmaceutical services in Brazilian primary health care: a cross-sectional study. BMC Primary Care, v. 22, n. 41, 2021. DOI: https://doi.org/10.1186/s12875-021-01516-7
ROQUE, N. C.; MACHADO, V. F.; CAZARIM, M. S. Clinical impact of medication therapy management by pharmaceutical care on hypertensive and diabetic patients in the context of the COVID-19 pandemic. Medicina (Ribeirão Preto), v. 56, n. 4, e209939, 2023. DOI: https://doi.org/10.11606/issn.2176-7262.rmrp.2023.209939
ROQUE, N. C.; MACHADO, V. F.; CAZARIM, M. S. Pharmaceutical care reducing the impact of the COVID-19 pandemic on the cardiovascular health of hypertensive and diabetic patients. Medicina (Ribeirão Preto, Online), Ribeirão Preto, v. 56, n. 4, p. e209939, 2023. doi: 10.11606/issn.2176-7262.rmrp.2023.209939. DOI: https://doi.org/10.11606/issn.2176-7262.rmrp.2023.209939
SILVA, D. L.; FARIAS, M. R. (2018). A importância da assistência farmacêutica na promoção da saúde e prevenção de doenças crônicas. Saúde e Sociedade, v. 27, n. 2, p. 394- 405.
SILVA, I. C. et al. Letramento em saúde e adesão ao tratamento farmacológico de pessoas com hipertensão arterial. Revista Brasileira de Enfermagem, Brasília, v. 75, n. 6, p. e20220008, 2022. DOI: https://doi.org/10.1590/0034-7167-2022-0008
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Lívia Celine Neves Carvalho, Joseana Martins Soares de Rodrigues Leitão
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in this journal agree to the following terms:
Authors retain copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Creative Commons Attribution License, which permits the sharing of the work with proper acknowledgment of authorship and initial publication in this journal;
Authors are authorized to enter into separate, additional agreements for the non-exclusive distribution of the version of the work published in this journal (e.g., posting in an institutional repository or publishing it as a book chapter), provided that authorship and initial publication in this journal are properly acknowledged, and that the work is adapted to the template of the respective repository;
Authors are permitted and encouraged to post and distribute their work online (e.g., in institutional repositories or on their personal websites) at any point before or during the editorial process, as this may lead to productive exchanges and increase the impact and citation of the published work (see The Effect of Open Access);
Authors are responsible for correctly providing their personal information, including name, keywords, abstracts, and other relevant data, thereby defining how they wish to be cited. The journal’s editorial board is not responsible for any errors or inconsistencies in these records.
PRIVACY POLICY
The names and email addresses provided to this journal will be used exclusively for the purposes of this publication and will not be made available for any other purpose or to third parties.
Note: All content of the work is the sole responsibility of the author and the advisor.
